CPC C07K 16/2863 (2013.01) [A61P 35/00 (2018.01); C07K 14/00 (2013.01); C07K 14/71 (2013.01); C07K 16/22 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2318/10 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01)] | 19 Claims |
1. A bispecific antagonist, comprising a first targeting domain and a second targeting domain:
wherein the first targeting domain binds specifically to human LAG-3 and comprises:
(1) an immunoglobulin HCVR comprising three HCDRs: HCDR1, HCDR2 and HCDR3,
wherein the HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 163, 166 and 169,
wherein the HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 164, 167 and 170, and
wherein the HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 165, 168 and 171; and
(2) an immunoglobulin LCVR comprising three LCDRs: LCDR1, LCDR2 and LCDR3,
wherein the LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 172, 175 and 177,
wherein the LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 173 and 178, and
wherein the LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOS; 174, 176 and 179.
|